FIELD: biotechnology.
SUBSTANCE: artificial gene bsi-cov-ub encoding an artificial polyepitope T-cell immunogen protein BSI-COV-Ub having the nucleotide sequence of SEQ ID No.: 2 containing on 5'-end sequence Kozak CCGCCACC; between the sequences encoding ubiquitin and BSI-COV there is a site for restriction endonuclease PspLI, and on 3'-end - two stop codons TAATGA and a site for restriction endonuclease ApaI. A recombinant plasmid DNA pBSI-COV-Ub having the nucleotide sequence of SEQ ID No.: 1 is also described. In addition, a polyepitope immunogen protein BSI-COV-Ub is described having the amino acid sequence of SEQ ID No.: 3, containing conserved epitopes from the S, E, M, N proteins of the SARS-CoV-2 virus, the universal T-helper epitope PADRE, a marker epitope that binds to known mAb 29F2, and an N-terminal ubiquitin that increases the efficiency of processing the immunogen synthesized in cell, by targeting the proteasome and inducing SARS-CoV-2-specific T-cell immunity.
EFFECT: creation of a safe and effective polyepitope T-cell vaccine DNA construction capable of inducing a specific cytotoxic and T-helper response against various strains of the SARS-CoV-2 virus.
4 cl, 8 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ARTIFICIAL GENE ENCODING THE BSI-COV IMMUNOGEN PROTEIN, PBSI-COV RECOMBINANT PLASMID DNA PROVIDING EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL BSI-COV POLYEPITOPE IMMUNOGEN PROTEIN CONTAINING EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2- SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806556C1 |
| PLASMID DNA MATRIX AND mRNA MOLECULE USED TO PRODUCE VACCINE AGAINST CORONAVIRUS, OBTAINED USING DNA MATRIX AND PROVIDING EXPRESSION OF GENE OF ARTIFICIAL POLYEPITOPIC PROTEIN-IMMUNOGEN CONTAINING CONSERVED EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC IMMUNITY | 2024 |
|
RU2839372C1 |
| ARTIFICIAL PROTEIN-IMMUNOGEN TCI COMPRISING MULTIPLE CTL-EPITOPES OF HIV-1 BASIC ANTIGENS, ARTIFICIAL GENE TCI ENCODING POLYEPITOPE PROTEIN-IMMUNOGEN TCI | 2002 |
|
RU2238946C2 |
| ARTIFICIAL GENE MEL-TCI, CODING POLYEPITOPIC PROTEIN-IMMUNOGENE MEL-TCI, RECOMBINANT PLASMID DNA PMEL-TCI PROVIDING EXPRESSION OF ARTIFICIAL GENE MEL-TCI AND ARTIFICIAL PROTEIN-IMMUNOGENE MEL-TCI, CONTAINING CTL- AND Th-DETERMINANTS OF MELANOMA ANTIGENES RESTRUCTURED BY PLURAL ALLELS HLA OF I AND II CLASS | 2017 |
|
RU2650872C1 |
| MEL-TCI-A0201 ARTIFICIAL GENE CODING MEL-TCI-A0201 POLYEPITOPE IMMUNOGENIC PROTEIN, RECOMBINANT PLASMID DNA OF pMEL-TCI-A0201, PROVIDING EXPRESSION OF MEL-TCI-A0201 ARTIFICIAL GENE AND MEL-TCI-A0201 ARTIFICIAL IMMUNOGENIC PROTEIN CONTAINING MULTIPLE CTL- AND Th-EPITOPES OF MELANOMA ANTIGENS | 2012 |
|
RU2522830C2 |
| ARTIFICIAL GENE N1NEW, ENCODING NUCLEOCAPSID PROTEIN OF CORONAVIRUS SARS-CoV-2, AND RECOMBINANT PLASMID PET-28A-N1NEW, PROVIDING EXPRESSION OF THE ARTIFICIAL GENE | 2021 |
|
RU2762962C1 |
| ARTIFICIAL GENES CODING EV.CTL AND EV.Th PROTEINS-IMMUNOGENS, RECOMBINANT PLASMID DNA pEV.CTL AND EV.Th, PROVIDING EXPRESSION OF ARTIFICIAL GENES, AND ARTIFICIAL T-CELL POLYEPITOPE PROTEINS-IMMUNOGENS EV.CTL AND EV.Th CONTAINING EPITOPES OF EBOLA VIRUS ANTIGENS, USED TO CREATE AN EBOLA VIRUS VACCINE | 2018 |
|
RU2713723C1 |
| CONJUGATE OF THE RECEPTOR-BINDING DOMAIN (RBD) PROTEIN OF SARS-CoV-2 SURFACE GLYCOPROTEIN S WITH POLYGLUCIN-SPERMIDINE (PGS) POLYMER AND VACCINE COMPLEX AGAINST CORONAVIRUS INFECTION COVID-19 BASED ON THE SPECIFIED CONJUGATE AND PLASMID DNA PVAX-RBD | 2022 |
|
RU2781294C1 |
| INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
| RECOMBINANT STRAIN SEN-SDELTA(M) OF SENDAI VIRUS, PRODUCING S-PROTEIN SARS-CoV-2 AND USED TO PRODUCE INTRANASAL VACCINE AGAINST COVID-19 | 2024 |
|
RU2837536C1 |
